Equillium Inc
Veridion Score
Composite trend over time
Why is EQ moving today?
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for EQ.
EQ insider activity
Equillium Inc
2 insiders bought in the last 90 days
Net selling: -$2.0M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-05 | 2026-06-05 | Zedelmayer Christine | Insider | sell | $2.93 | 14,584 | 62,586 | $43K | SEC Form 4 |
| 2026-06-05 | 2026-06-05 | Zedelmayer Christine | Insider | buy | $0.79 | 14,584 | 77,170 | $11K | SEC Form 4 |
| 2026-06-05 | 2026-06-05 | Connelly Stephen | Insider | sell | $2.94 | 30,975 | 762,025 | $91K | SEC Form 4 |
| 2026-06-05 | 2026-06-04 | Connelly Stephen | Insider | sell | $3.16 | 200,000 | 793,000 | $633K | SEC Form 4 |
| 2026-05-29 | 2026-05-28 | Tom Penny | Insider | sell | $2.95 | 65,000 | Not reported | $192K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 31 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moEQ contract awards, year to date.
Public federal awards linked to this ticker.
EQ lobbying filings, year to date.
Registered lobbying filings matched to Equillium Inc.